Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 7494.41
GNMSF's Cash to Debt is ranked higher than
76% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. GNMSF: 7494.41 )
GNMSF' s 10-Year Cash to Debt Range
Min: 4.76   Max: No Debt
Current: 7494.41

Equity to Asset 0.71
GNMSF's Equity to Asset is ranked higher than
75% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNMSF: 0.71 )
GNMSF' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.93
Current: 0.71

0.23
0.93
F-Score: 7
Z-Score: 20.49
M-Score: -1.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 31.18
GNMSF's Operating margin (%) is ranked higher than
97% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. GNMSF: 31.18 )
GNMSF' s 10-Year Operating margin (%) Range
Min: -434.42   Max: 10760.13
Current: 31.18

-434.42
10760.13
Net-margin (%) 35.43
GNMSF's Net-margin (%) is ranked higher than
97% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. GNMSF: 35.43 )
GNMSF' s 10-Year Net-margin (%) Range
Min: -10124.65   Max: 35.43
Current: 35.43

-10124.65
35.43
ROE (%) 18.51
GNMSF's ROE (%) is ranked higher than
95% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. GNMSF: 18.51 )
GNMSF' s 10-Year ROE (%) Range
Min: -112.03   Max: 22.38
Current: 18.51

-112.03
22.38
ROA (%) 11.64
GNMSF's ROA (%) is ranked higher than
95% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. GNMSF: 11.64 )
GNMSF' s 10-Year ROA (%) Range
Min: -36.89   Max: 13.1
Current: 11.64

-36.89
13.1
ROC (Joel Greenblatt) (%) 1116.59
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. GNMSF: 1116.59 )
GNMSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -675.71   Max: 1097
Current: 1116.59

-675.71
1097
Revenue Growth (3Y)(%) 23.90
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
90% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. GNMSF: 23.90 )
GNMSF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 331.5
Current: 23.9

0
331.5
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 97.60
GNMSF's P/E(ttm) is ranked higher than
87% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 97.60 )
GNMSF' s 10-Year P/E(ttm) Range
Min: 42.72   Max: 112.63
Current: 97.6

42.72
112.63
PE(NRI) 97.60
GNMSF's PE(NRI) is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 97.60 )
GNMSF' s 10-Year PE(NRI) Range
Min: 42.64   Max: 181.04
Current: 97.6

42.64
181.04
P/B 14.40
GNMSF's P/B is ranked lower than
55% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. GNMSF: 14.40 )
GNMSF' s 10-Year P/B Range
Min: 1.63   Max: 25.05
Current: 14.4

1.63
25.05
P/S 33.50
GNMSF's P/S is ranked higher than
54% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. GNMSF: 33.50 )
GNMSF' s 10-Year P/S Range
Min: 3.08   Max: 42.95
Current: 33.5

3.08
42.95
PFCF 530.40
GNMSF's PFCF is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 530.40 )
GNMSF' s 10-Year PFCF Range
Min: 3.77   Max: 579.8
Current: 530.4

3.77
579.8
POCF 222.73
GNMSF's POCF is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 222.73 )
GNMSF' s 10-Year POCF Range
Min: 3.67   Max: 236.8
Current: 222.73

3.67
236.8
EV-to-EBIT 105.54
GNMSF's EV-to-EBIT is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 105.54 )
GNMSF' s 10-Year EV-to-EBIT Range
Min: -390.4   Max: 1407.3
Current: 105.54

-390.4
1407.3
Current Ratio 4.22
GNMSF's Current Ratio is ranked higher than
72% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. GNMSF: 4.22 )
GNMSF' s 10-Year Current Ratio Range
Min: 1.4   Max: 17.04
Current: 4.22

1.4
17.04
Quick Ratio 4.22
GNMSF's Quick Ratio is ranked higher than
73% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. GNMSF: 4.22 )
GNMSF' s 10-Year Quick Ratio Range
Min: 1.4   Max: 17.04
Current: 4.22

1.4
17.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.00
GNMSF's Price/Net Cash is ranked higher than
67% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. GNMSF: 16.00 )
GNMSF' s 10-Year Price/Net Cash Range
Min: 10.42   Max: 75.2
Current: 16

10.42
75.2
Price/Net Current Asset Value 16.00
GNMSF's Price/Net Current Asset Value is ranked higher than
66% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. GNMSF: 16.00 )
GNMSF' s 10-Year Price/Net Current Asset Value Range
Min: 2.89   Max: 17.67
Current: 16

2.89
17.67
Price/Tangible Book 14.90
GNMSF's Price/Tangible Book is ranked lower than
52% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. GNMSF: 14.90 )
GNMSF' s 10-Year Price/Tangible Book Range
Min: 1.62   Max: 22.67
Current: 14.9

1.62
22.67
Price/DCF (Projected) 83.90
GNMSF's Price/DCF (Projected) is ranked higher than
87% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 83.90 )
GNMSF' s 10-Year Price/DCF (Projected) Range
Min: 58.68   Max: 58.68
Current: 83.9

Price/Median PS Value 3.80
GNMSF's Price/Median PS Value is ranked higher than
63% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. GNMSF: 3.80 )
GNMSF' s 10-Year Price/Median PS Value Range
Min: 0.54   Max: 2.64
Current: 3.8

0.54
2.64
Price/Graham Number 8.00
GNMSF's Price/Graham Number is ranked higher than
88% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GNMSF: 8.00 )
GNMSF' s 10-Year Price/Graham Number Range
Min: 5.62   Max: 10.78
Current: 8

5.62
10.78
Earnings Yield (Greenblatt) 0.90
GNMSF's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. GNMSF: 0.90 )
GNMSF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 456.1
Current: 0.9

0.1
456.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S, incorporated on June 11, 1998, is a biotechnology company that utilizes antibody products. The Company's first marketed antibody, ofatumumab (Arzerra), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed under a co-development and collaboration agreement with GlaxoSmithKline and has been launched in over two dozen countries. In addition to ofatumumab, it is building a pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need. Its product pipeline includes four antibodies in clinical development and over ten active pre-clinical programs.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK